Bionik Laboratories Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BNKL research report →
Price Chart
About the company
Bionik Laboratories Corp. operates as a robotics firm, focusing on the innovation, development, and market introduction of advanced solutions for physical rehabilitation, prosthetic devices, and assistive robotics. The company's product range features the InMotion Robots, a comprehensive collection of robotic therapy tools.
- CEO
- Richard Paul Russo Jr.
- IPO
- 2015
- Employees
- 12
- HQ
- Watertown, MA, US
Get TickerSpark's AI analysis on BNKL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.25K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.42
- Div Yield
- 0.00%
- Gross Margin
- 54.83%
- Op Margin
- -267.29%
- Net Margin
- -273.99%
- ROE
- -768.84%
- ROIC
- -448.84%
Latest fiscal year · YoY change
- Revenue
- $1.81M+41.7%
- Gross Profit
- $989.88K+3.8%
- Op Income
- $-4,825,039
- Net Income
- $-4,946,024+52.5%
- EPS
- $-0.72+59.6%
- OCF Growth
- +18.3%
- FCF Growth
- +18.6%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 9.36
- RSI (14)
- 52
- Avg Volume
- 533
No earnings-call transcripts are available for BNKL yet.
- Free Float
- 5.9%
- Shares Outstanding
- 12.48M
- Float Shares
- 735.73K
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 13, 23 | Gaston-Dreyfus Remi | other | 3,102,878 |
| Jun 13, 23 | AUBERTON-HERVE ANDRE-JACQUES | other | 186,111 |
| Jun 13, 23 | AUBERTON-HERVE ANDRE-JACQUES | buy | 1 |
| Jun 9, 23 | Matine Charles | buy | 180,555 |
| Jun 9, 23 | Gaston-Dreyfus Remi | buy | 180,555 |
| Jun 9, 23 | AUBERTON-HERVE ANDRE-JACQUES | buy | 650,000 |
| Oct 6, 23 | Gonsalves Daniel | other | 60,000 |
| Oct 6, 22 | Russo Richard Paul Jr | other | 60,000 |
| Jul 15, 21 | AUBERTON-HERVE ANDRE-JACQUES | other | 7,500 |
| Jul 15, 21 | AUBERTON-HERVE ANDRE-JACQUES | other | 51,878 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BNKL coverage
Recent articles, reports, and earnings notes.
No research on BNKL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BNKL report →Bionik Laboratories Granted United States Patent for Innovative Rehabilitation Technology
businesswire.com · Sep 14
Bionik Laboratories Enters into Distribution Agreement with Pro-Med Technology for the Sale of InMotion® Robotic Devices in Hong Kong
headlinesoftoday.com · May 4
BIONIK Laboratories to Present at National Investment Banking Association Conference
accesswire.com · Sep 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.